Vancouver, BC and Montreal, QC: adMare BioInnovations, Canada’s Global Life Sciences Venture, is pleased to announce the appointment of Dr. Mounia Azzi as Vice President, Program Development and Partnerships. As a member of adMare’s senior management team, Dr. Azzi will lead the project identification and scientific and commercial evaluation process, ensuring a robust and strategically diverse pipeline for the organization.
With deep experience in corporate and business development, serving most recently as the Executive Global Vice President, Corporate Development (and previously Chief Business Officer) at Nexelis, Dr. Azzi will work closely with adMare’s Venture Partners to build their portfolios through new program creation, asset identification and investment area development. In doing so, she will play a key role in advancing adMare’s Mission to source therapeutically and commercially promising research from leading academic and biotech partners from across Canada to create and grow companies of scale.
Gordon C. McCauley, President and CEO of adMare BioInnovations said, “We are thrilled that Dr. Azzi has joined adMare. Mounia has lived the journey from academic innovation to commercial program. With extensive experience in multiple therapeutic areas, credibility and standing among key academic partners, and a deep knowledge of business development, investment management, and value creation, Mounia is exactly the right person to work with academic and industry partners across the country to build new collaborations leading to strong Canadian life sciences companies of scale.”
“With my combined passion for therapeutic drug development and seeing academic discoveries become valuable commercial projects, I am excited to begin in this new role,” said Dr. Mounia Azzi, Vice President, Program Development and Partnerships, adMare BioInnovations. “Canada needs to translate our tremendous research excellence into more life science companies of scale, and no one is doing more in this regard than adMare. I am eager to start working to truly change the landscape of the Canadian life sciences ecosystem.”
Prior to joining Nexelis, Dr. Azzi was Director, Scientific Affairs at the NEOMED Institute, responsible for the identification and evaluation of new opportunities to complement NEOMED’s prospecting activities. Previously, she was Director of Programs at CQDM, where she was responsible for the evaluation and management of research projects and funding programs. Earlier roles included Investment Manager at MSBi Valorization, where she covered all aspects of the valorization and investment process, including identification, evaluation, due diligence, negotiation, and fundraising for opportunities in the life sciences sector. She was also actively involved in business development activities with industry partners. She started her career as leader of the cellular biology group at Bellus Health (formerly Neurochem Inc.), where she was involved in the development of therapeutics targeting Alzheimer’s disease and diabetes. Dr. Azzi holds a PhD in Neuroscience from Université Pierre et Marie Curie (UPMC) in Paris.
– 30 –
About adMare BioInnovations
adMare BioInnovations is Canada’s Global Life Sciences Venture, changing the landscape of the Canadian life sciences ecosystem from sea to sea. We do this by sourcing therapeutically and commercially promising research from leading academic and biotech partners to create new companies of scale, providing specialized expertise and infrastructure to help existing companies scale up, and driving the growth of those companies into Canadian anchors by training the next generation of highly-qualified personnel. www.admarebio.com
For additional information, please contact:
Senior Manager, Communications
604.827.1226 | email@example.com